Sunday, November 5, 2017
- 9:00AM-11:00AM
-
Abstract Number: 142
Incidence of Hip Fracture in Rheumatoid Arthritis: British Columbia, Canada
Epidemiology and Public Health Poster I: Rheumatoid Arthritis- 9:00AM-11:00AM
-
Abstract Number: 545
Incidence of Infusion Reactions to Intravenous Golimumab: Results from a Prospective, Real-World Community Registry
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster I: Comorbidities and Adverse Events; Efficacy and Safety of Small Molecules- 9:00AM-11:00AM
-
Abstract Number: 102
Incorporating Temporal Artery Ultrasound in a UK District General Hospital with No Prior Colour Doppler Sonography Service: An Encouraging Preliminary Analysis
Education Poster- 9:00AM-11:00AM
-
Abstract Number: 761
Increased Expression of the TNF Superfamily Member LIGHT/TNFSF14 and Its Receptor (TNFRSF14) in Patients with Systemic Sclerosis
Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics Poster I- 9:00AM-11:00AM
-
Abstract Number: 488
Increased Expression of TNF-α and PAD-2 in Human Monocytes Following Treatment with Protein Modified with Malondialdehyde-Acetaldehyde (MAA) and Citrulline
Rheumatoid Arthritis – Human Etiology and Pathogenesis Poster I- 9:00AM-11:00AM
-
Abstract Number: 18
Increased Frequency of Nailfold Videocapillaroscopy Abnormalities in Primaryantiphospolipid (PAPS) Patients
Antiphospholipid Syndrome Poster- 9:00AM-11:00AM
-
Abstract Number: 766
Increased Plasma Levels of Hsp90 Are Associated with More Severe Organ Involvement in Patients with Systemic Sclerosis
Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics Poster I- 9:00AM-11:00AM
-
Abstract Number: 549
Increases in Lipid Levels Following Sirukumab Treatment Are Associated with Suppression of Inflammation in Rheumatoid Arthritis: Results from Two Phase 3 Trials
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster I: Comorbidities and Adverse Events; Efficacy and Safety of Small Molecules- 9:00AM-11:00AM
-
Abstract Number: 199
Incremental Direct Medical Costs of Systemic Lupus Erythematosus Patients in the Years Preceding Diagnosis and the Impact of Sex: A General Population-Based Study
Health Services Research Poster I- 9:00AM-11:00AM
-
Abstract Number: 388
Induction of Anti-Citrullinated Protein Antibodies By Peptidyl Arginine Deiminase Immunization: A New Model for the Development of Anti-Citrullinated Protein Antibodies in Rheumatoid Arthritis
Rheumatoid Arthritis – Animal Models Poster I- 9:00AM-11:00AM
-
Abstract Number: 591
Inflammation on MRI of Spine and Sacroiliac Joints Is Highly Predictive of Structural Damage in Axial Spondyloarthritis: The 5 Years Data of the DESIR Cohort
Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster I- 9:00AM-11:00AM
-
Abstract Number: 588
Inflammatory Lesions of the Sacroiliac Joints, but Not of the Spine, Are of High Utility for Recent Onset Axial Spondyloarthritis Recognition
Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster I- 9:00AM-11:00AM
-
Abstract Number: 208
Influence of Depression on Healthcare Expenditures Among Adults with Spondylosis, Intervertebral Disc Disorders and Other Back Problems in the United States
Health Services Research Poster I- 9:00AM-11:00AM
-
Abstract Number: 468
Initiation of Biologic Disease Modifying Antirheumatic Drug Therapy and Associated Changes in Disease Activity Measures in Routine Clinical Practice: Findings from a Large Contemporaneous Real World Cohort
Rheumatoid Arthritis – Clinical Aspects Poster I: Treatment Patterns and Response- 9:00AM-11:00AM
-
Abstract Number: 655
Innate Lymphoid Cells – New Players in Psoriatic Arthritis